Application of reagent or method for inhibiting growth hormone receptor and / or JAK2 signal channel in preparation of product for treating gastrointestinal stromal tumor and / or complications thereof

By inhibiting growth hormone receptors and JAK2 signaling pathways and combining gastrointestinal stromal tumor targeted drugs, the targeted drug resistance and hypoglycemia problems in gastrointestinal stromal tumor treatment have been solved, and cell proliferation inhibition has been achieved. Apoptosis promotes and improves blood sugar, prolongs patient survival.

CN119033941APending Publication Date: 2024-11-29NINGXIA MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411459213.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-18
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The prior art has the problem of targeted drug resistance in the treatment of gastrointestinal stromal tumors, and cannot effectively solve the complications of hypoglycemia, resulting in limited treatment effects and high risk of recurrence.

Method used

By inhibiting growth hormone receptors and JAK2 signaling pathways, using siRNA transfection or fidatinib, combined with gastrointestinal stromal tumor targeting drugs such as imatinib, it inhibits cell proliferation and survival, promotes apoptosis, and improves Sensitivity to targeted drugs and reduces the expression of insulin-like growth factor 2 and improves blood sugar levels.

Benefits of technology

Effectively inhibit the proliferation and survival of gastrointestinal stromal tumor cells, promote apoptosis, enhance sensitivity to targeted drugs, improve patients' blood sugar levels, prolong survival and reduce hypoglycemia attacks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033941A_ABST
    Figure CN119033941A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of a reagent or a method for inhibiting a growth hormone receptor and / or a JAK2 signal channel in preparation of a product for treating gastrointestinal stromal tumor and / or complications thereof. It is found that by inhibiting the growth hormone receptor, proliferation and survival of gastrointestinal stromal tumor cells can be inhibited, activation of AKT, ERK and STAT5 in the gastrointestinal stromal tumor cells can be inhibited, the sensitivity of the gastrointestinal stromal tumor to targeted drugs of the gastrointestinal stromal tumor is improved, expression of insulin-like growth factor 2 in the gastrointestinal stromal tumor is inhibited, the blood glucose level is improved, and the gastrointestinal stromal tumor can be used for treating the gastrointestinal stromal tumor. Therefore, the effect of treating gastrointestinal stromal tumor and / or complications thereof is achieved; in addition, by inhibiting a downstream JAK2 signal channel of a growth hormone receptor, proliferation and survival of gastrointestinal stromal tumor cells can also be inhibited, cell apoptosis is promoted, and sensitivity of the cells to imatinib is enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of an agent or method for inhibiting growth hormone receptor and / or JAK2 signaling pathway in the preparation of a product for treating gastrointestinal stromal tumors and / or their complications. Background Art

[0002] Gastrointestinal stromal tumors (GIST) originate from the mesenchymal tissue of the gastrointestinal tract. They are a rare tumor that occurs in the digestive tract, accounting for 1% to 3% of gastrointestinal malignant tumors. The estimated annual incidence is about (10 to 20) / 1 million, and 20% to 30% are malignant.

[0003] At present, the clinical treatment of gastrointestinal stromal tumors mainly relies on surgical treatment and targeted drug therapy. Among them, surgical treatment is suitable for primary localized gastrointestinal stromal tumors and recurrent metastatic tumors that can be completely removed by surgery. However, high-risk patients still have a high risk of recurrence and metastasis after surgery. In addition, due to the insidious onset of the disease and the lack of specific clinical symptoms, most patients are already in the middle and late stages when they seek medical treatment, missing the opportunity for surgery. For patients who cannot undergo surgery, targeted drug therapy can be selectively given. Among them, imatinib, the first-line targeted treatment drug for this tumor, has a significant effect and can significantly prolong the patient's survival. However, it mainly targets the main mutant gene c-Kit that causes gastrointestinal stromal tumors. Generally, after an average of 24 months of treatment, drug resistance will occur, greatly affecting the patient's prognosis. Targeted therapy resistance often leads to treatment failure in the end. Although there are second-, third-, and fourth-line drugs to choose from, their efficacy is very limited. They can only prolong the patient's survival by a few months and cannot completely control gastrointestinal stromal tumors.

[0004] In addition, many papers have reported that gastrointestinal stromal tumors can cause hypoglycemia in patients. These patients are generally given glucose or glucagon to improve the symptoms of hypoglycemia, but these treatments cannot fundamentally solve the patient's hypoglycemia problem. Without surgical removal of the tumor or effective targeted therapy, patients will still be hospitalized due to repeated episodes of hypoglycemia. Summary of the invention

[0005] The purpose of the present invention is to provide an agent or method for inhibiting growth hormone receptor and / or JAK2 signaling pathway for use in the preparation of a product for treating gastrointestinal stromal tumor and / or its complications, inhibiting the proliferation of gastrointestinal stromal tumor cells, promoting gastrointestinal stromal tumor cell apoptosis, and enhancing the sensitivity of gastrointestinal stromal tumor cells to gastrointestinal stromal tumor targeted drugs, so that the blood sugar of gastrointestinal stromal tumor patients can be restored, and gastrointestinal stromal tumor and / or hypoglycemia complicated by gastrointestinal stromal tumor can be treated.

[0006] The present invention provides the use of an agent or method for inhibiting growth hormone receptor and / or JAK2 signaling pathway in preparing a product for treating gastrointestinal stromal tumors and / or its complications.

[0007] The present invention also provides the use of an agent or method for inhibiting growth hormone receptor and / or JAK2 signaling pathway in combination with a gastrointestinal stromal tumor targeted drug in the preparation of a product for treating gastrointestinal stromal tumor and / or its complications.

[0008] Preferably, the gastrointestinal stromal tumor targeted drug includes imatinib.

[0009] Preferably, the complication of gastrointestinal stromal tumor includes gastrointestinal stromal tumor complicated by hypoglycemia.

[0010] Preferably, the growth hormone receptor inhibiting agent comprises a siRNA transfection agent;

[0011] The agent that inhibits the JAK2 signaling pathway includes Fidatinib.

[0012] Preferably, the siRNA transfection reagent comprises siRNA, and the nucleotide sequence of the siRNA is shown as SEQ ID NO.2 or SEQ ID NO.3.

[0013] Preferably, the method for inhibiting growth hormone receptor comprises siRNA transfection.

[0014] Preferably, the product for treating gastrointestinal stromal tumors and / or its complications includes one or more of the following;

[0015] (1) Products that inhibit the proliferation and / or survival of gastrointestinal stromal tumor cells;

[0016] (2) Products that promote apoptosis of gastrointestinal stromal tumor cells;

[0017] (3) products that inhibit activation of one or more of AKT, ERK, and STAT5 in gastrointestinal stromal tumor cells;

[0018] (4) Products that increase the sensitivity of gastrointestinal stromal tumors to gastrointestinal stromal tumor-targeted drugs;

[0019] (5) Products that inhibit the expression of insulin-like growth factor 2 in gastrointestinal stromal tumors and improve blood sugar levels.

[0020] The present invention also provides a drug for treating gastrointestinal stromal tumors and / or its complications, wherein the active ingredients of the drug include siRNA and / or a JAK2 inhibitor;

[0021] The nucleotide sequence of the siRNA is shown as SEQ ID NO.2 or SEQ ID NO.3.

[0022] Preferably, the active ingredient of the drug further includes a gastrointestinal stromal tumor targeted drug; the gastrointestinal stromal tumor targeted drug includes imatinib.

[0023] Beneficial effects:

[0024] The present invention finds that by inhibiting growth hormone receptors, it is possible to inhibit the proliferation of gastrointestinal stromal tumor cells, promote apoptosis of gastrointestinal stromal tumor cells, inhibit the activation of AKT, ERK and STAT5 in gastrointestinal stromal tumor cells, improve the sensitivity of gastrointestinal stromal tumors to gastrointestinal stromal tumor targeted drugs, inhibit the expression of insulin-like growth factor 2 in gastrointestinal stromal tumors, and improve the phenomenon of hypoglycemia caused by patients suffering from the tumor, thereby achieving the effect of treating gastrointestinal stromal tumors and / or its complications; and by inhibiting the JAK2 signaling pathway downstream of the growth hormone receptor, it is also possible to inhibit the proliferation and survival of gastrointestinal stromal tumor cells, promote cell apoptosis, and enhance the sensitivity of cells to imatinib. Reagents that inhibit growth hormone receptors and / or inhibit the JAK2 signaling pathway downstream of the growth hormone receptor can be used to prepare products for treating gastrointestinal stromal tumors and / or their complications, and indirectly prepare products for treating gastrointestinal stromal tumors and / or their complications. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the embodiments are briefly introduced below.

[0026] Figure 1 The results of immunohistochemical detection of growth hormone receptor expression in tumors and adjacent tissues of patients with clinical gastrointestinal stromal tumors in Example 1;

[0027] Figure 2 The Western blot test results of gastrointestinal stromal tumor cells GIST-T1 in different treatment groups in Example 3;

[0028] Figure 3 The proliferation of gastrointestinal stromal tumor cells GIST-T1 in different treatment groups in Example 4; wherein ** indicates P < 0.01;

[0029] Figure 4 The flow cytometric detection results of gastrointestinal stromal tumor cells GIST-T1 in different treatment groups in Example 4;

[0030] Figure 5 The cell apoptosis of gastrointestinal stromal tumor cells GIST-T1 in different treatment groups in Example 4; where * indicates P < 0.05, and ** indicates P < 0.01;

[0031] Figure 6The proliferation of gastrointestinal stromal tumor cells GIST-T1 in different treatment groups in Example 5; where * indicates P < 0.05, and *** indicates P < 0.001;

[0032] Figure 7 The flow cytometric detection results of gastrointestinal stromal tumor cells GIST-T1 in different treatment groups in Example 5;

[0033] Figure 8 The cell apoptosis of gastrointestinal stromal tumor cells GIST-T1 in different treatment groups in Example 5; where * indicates P < 0.05, and ** indicates P < 0.01;

[0034] Fig. 9 The Western blot test results for verifying the expression of insulin-like growth factor 2 in Example 7;

[0035] Fig.10 is the blood glucose level of mice in different treatment groups; where * indicates P < 0.05, KIT gene belongs to the type III tyrosine kinase receptor family and is one of the main oncogenes that cause gastrointestinal stromal tumors (accounting for more than 70%), and GHR is the growth hormone receptor. DETAILED DESCRIPTION

[0036] The present invention provides the use of an agent or method for inhibiting growth hormone receptor and / or JAK2 signaling pathway in preparing a product for treating gastrointestinal stromal tumors and / or its complications.

[0037] The present invention also provides the use of an agent or method for inhibiting growth hormone receptor and / or JAK2 signaling pathway in combination with a gastrointestinal stromal tumor targeted drug in the preparation of a product for treating gastrointestinal stromal tumor and / or its complications. In the present invention, the gastrointestinal stromal tumor targeted drug preferably includes imatinib.

[0038] In the present invention, the complication of gastrointestinal stromal tumor preferably includes gastrointestinal stromal tumor complicated with hypoglycemia. The reagent for inhibiting the expression of growth hormone receptor in the present invention preferably includes siRNA transfection reagent; the method for inhibiting the expression of growth hormone receptor preferably includes siRNA transfection. The siRNA transfection reagent in the present invention preferably includes siRNA, and the nucleotide sequence of the siRNA is preferably as shown in SEQ ID NO.2 or SEQ ID NO.3, specifically: SEQ ID NO.2: 5'-GCAACCAGAUCCACCCAUUNN-3', wherein N is A, T, C or G; SEQ ID NO.3: 5'-GUCAGUUUAACUGGGAUUCAUNN-3', wherein N is A, T, C or G. The reagent for inhibiting the JAK2 signaling pathway in the present invention preferably includes Fidatinib.

[0039] The present invention utilizes siRNA to knock down growth hormone receptors, and knocking down growth hormone receptor expression can inhibit the activation of AKT, ERK and STAT5 in gastrointestinal stromal tumor cells, inhibit the expression of insulin-like growth factor 2 in gastrointestinal stromal tumors, and improve the patient's blood sugar level, thereby achieving the effect of treating gastrointestinal stromal tumors and / or its complications; and the present invention utilizes agents that inhibit the JAK2 signaling pathway to inhibit the JAK2 signaling pathway downstream of the growth hormone receptor, inhibit the proliferation and survival of gastrointestinal stromal tumor cells, promote cell apoptosis, and enhance the sensitivity of cells to imatinib. The complications of gastrointestinal stromal tumors described in the present invention preferably include gastrointestinal stromal tumors complicated by hypoglycemia; both of the above methods can inhibit the proliferation and / or survival of gastrointestinal stromal tumor cells, promote gastrointestinal stromal tumor cell apoptosis, and increase the sensitivity of gastrointestinal stromal tumors to gastrointestinal stromal tumor targeted drugs, and the gastrointestinal stromal tumor targeted drugs preferably include imatinib.

[0040] The present invention also provides a drug for treating gastrointestinal stromal tumors and / or its complications, wherein the active ingredients of the drug include siRNA and / or a JAK2 inhibitor; the nucleotide sequence of the siRNA is shown in SEQ ID NO.2 or SEQ ID NO.3.

[0041] In the present invention, the JAK2 inhibitor preferably includes Fidatinib. The active pharmaceutical ingredient of the present invention preferably also includes a gastrointestinal stromal tumor targeted drug; the gastrointestinal stromal tumor targeted drug preferably includes imatinib.

[0042] To further illustrate the present invention, the application of the reagent or method for inhibiting the expression of growth hormone receptor provided by the present invention in the preparation of products for treating gastrointestinal stromal tumors and / or its complications is described in detail below in conjunction with the accompanying drawings and examples, but they should not be construed as limiting the scope of protection of the present invention.

[0043] Example 1

[0044] Expression of growth hormone receptor in gastrointestinal stromal tumors

[0045] Thirty samples of clinical gastrointestinal stromal tumor (GIST) and their adjacent tissues were collected. The expression of growth hormone receptor (GHR) in different samples was detected by immunohistochemistry (refer to the existing technology: Zhang Shaoting, Zhang Liangying, Zhang Dan et al. Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling [J]. Molecular Carcinogenesis). The results showed that GIST expressed GH receptor at a higher level than adjacent tissues ( Figure 1 ).

[0046] Example 2

[0047] siRNA synthesis

[0048] Tianjin Sheweisi Biotechnology Co., Ltd. was commissioned to design and synthesize the following siRNA:

[0049] con siRNA: 5'-UUCUCCGAACGUGUCACGUNN-3', recorded as SEQ ID NO.1, in this embodiment, N is specifically T;

[0050] GHR siRNA-A: 5'-GCAACCAGAUCCACCCAUUNN-3', recorded as SEQ ID NO. 2, in this example, N is specifically T;

[0051] GHR siRNA-B: 5'-GUCAGUUUAACUGGGAUUCAUNN-3', recorded as SEQ ID NO.3. In this example, N is specifically T.

[0052] Example 3

[0053] Gastrointestinal stromal tumor cells GIST-T1 were randomly divided into three treatment groups and treated as follows:

[0054] Treatment group 1: referring to the prior art (Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling), con siRNA was transfected into gastrointestinal stromal tumor cells GIST-T1, and cultured in RPMI-1640 medium containing 15% fetal bovine serum and 1% penicillin-streptomycin mixture;

[0055] Treatment group 2: In the same manner as treatment group 1, GHR siRNA-A was transfected into gastrointestinal stromal tumor cells GIST-T1 and cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin;

[0056] Treatment group 3: In the same manner as treatment group 1, GHR siRNA-B was transfected into gastrointestinal stromal tumor cells GIST-T1 and cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin.

[0057] After 48 hours of culture in each treatment group, the cells were starved with empty culture medium for 4 hours, the cells were lysed to extract proteins, and Western blot was performed. The results showed that in gastrointestinal stromal tumor cells GIST-T1, the expression of growth hormone receptor can promote the activation of signal molecules AKT, ERK, and STAT5, thereby promoting tumor proliferation and survival ( Figure 2 ).

[0058] Example 4

[0059] Gastrointestinal stromal tumor cells GIST-T1 were randomly divided into 6 treatment groups and treated as follows:

[0060] Treatment group 1: The same method as in Example 3 was used to transfect con siRNA into gastrointestinal stromal tumor cells GIST-T1, and cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin;

[0061] Treatment group 2: The same method as in Example 3 was used, in which con siRNA was transfected into gastrointestinal stromal tumor cells GIST-T1, and the cells were cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin, and treated with a low concentration (0.0125 μM) of imatinib, a targeted therapeutic drug for gastrointestinal stromal tumors;

[0062] Treatment group 3: The same method as in Example 3 was used to transfect GHR siRNA-A into gastrointestinal stromal tumor cells GIST-T1, and cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin;

[0063] Treatment group 4: The same method as in Example 3 was used, GHR siRNA-A was transfected into gastrointestinal stromal tumor cells GIST-T1, and the cells were cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin, and treated with a low concentration (0.0125 μM) of imatinib, a targeted therapeutic drug for gastrointestinal stromal tumors;

[0064] Treatment group 5: The same method as in Example 3 was adopted, GHR siRNA-B was transfected into gastrointestinal stromal tumor cells GIST-T1, and cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin.

[0065] Treatment group 6: The same method as in Example 3 was adopted, GHR siRNA-B was transfected into gastrointestinal stromal tumor cells GIST-T1, and cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin, and treated with a low concentration (0.0125 μM) of imatinib, a targeted therapeutic drug for gastrointestinal stromal tumors.

[0066] After culturing the cells in each treatment group for 72 hours, the OD value of the cells in each treatment group at a wavelength of 490 nm was detected by MTT method to evaluate cell proliferation, and cell apoptosis was detected by flow cytometry. The results showed that knocking down the expression of growth hormone receptor in gastrointestinal stromal tumor cells could inhibit cell proliferation, promote cell apoptosis, and enhance the sensitivity of cells to imatinib ( Figures 3 to 5 ).

[0067] Example 5

[0068] Gastrointestinal stromal tumor cells GIST-T1 were randomly divided into 4 treatment groups and treated as follows:

[0069] Treatment group 1: The cells were cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin. The JAK2 inhibitor Fedratinib was dissolved in DMSO and added to the cell culture medium to a final concentration of 400 nM.

[0070] Treatment group 2: The cells were cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin, and DMSO was added to the cell culture medium in the same amount as that of the treatment group 1;

[0071] Treatment group 3: The cells were cultured in RPMI-1640 medium containing 15% fetal bovine serum and 1% penicillin-streptomycin mixture. Fedratinib, a JAK2 inhibitor, was dissolved in DMSO and added to the cell culture medium to a final concentration of 400 nM. Imatinib, a targeted therapeutic drug for gastrointestinal stromal tumors, was added to the culture medium at a low concentration (0.0125 μM).

[0072] Treatment group 4: The cells were cultured in RPMI-1640 medium containing a mixture of 15% fetal bovine serum and 1% penicillin-streptomycin, DMSO was added to the cell culture medium in the same amount as that of the treatment group 1, and a low concentration (0.0125 μM) of imatinib, a targeted therapeutic drug for gastrointestinal stromal tumors, was added.

[0073] After 72 hours of cell culture in each treatment group, the proliferation of cells in each treatment group was detected by MTT method, and cell apoptosis was detected by flow cytometry. The results showed that the use of Fedratinib, an inhibitor of JAK2, a downstream signaling molecule of growth hormone receptor, on gastrointestinal stromal tumor cells could inhibit the proliferation and survival of gastrointestinal stromal tumor cells, promote cell apoptosis, and enhance the sensitivity of cells to imatinib ( Figures 6 to 8 ).

[0074] Example 6

[0075] Animal experiments

[0076] The KIT gene belongs to the type III tyrosine kinase receptor family and is one of the main oncogenes that cause gastrointestinal stromal tumors (accounting for more than 70%). After the mouse KIT site mutation (V558A) occurs, the mouse can spontaneously develop gastrointestinal stromal tumors. Based on this principle, we commissioned Saiye Biotechnology Co., Ltd. to mutate the 558th position A of the KIT gene of wild C57BL / 6N mice (WT) to V (V558A) through CRISPR / Cas-mediated genome engineering, and obtain a gastrointestinal stromal tumor mouse model with KIT gene mutation (KIT V558A / WT ), knocked out the growth hormone receptor (GHR gene) in a gastrointestinal stromal tumor mouse model through CRISPR / Cas-mediated genome engineering, and the results showed that KIT V558A / WT The survival period of mice was extended from 4 to 5 months to more than 9 months. Therefore, the growth hormone receptor shortened the survival period of tumor-bearing mice.

[0077] Example 7

[0078] Treatment of hypoglycemia in patients with gastrointestinal stromal tumors

[0079] According to reports in literature 1 to 7, some patients with gastrointestinal stromal tumors were hospitalized due to hypoglycemia. The reason is that the tumor secretes insulin-like growth factor 2 (IGF2), which binds to insulin receptors after entering the blood circulation, causing the patient's blood sugar level to decrease. The present invention first collects blood sugar data of clinical patients and verifies that gastrointestinal stromal tumors can indeed cause patients' blood sugar levels to decrease. Even if the blood sugar levels of some patients are within the normal range, their blood sugar levels are still lower than those of normal people.

[0080] Document 1: A case of insulin-like growth factor2-producing gastrointestinalstromal tumor with severe hypoglycemia

[0081] Document 2: Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongatatumour, adrenalaladenoma, and follicularthyroid nodules

[0082] Document 3: Big-Insulin-Like Growth Factor-II Signaling Is anAutocrineSurvival Pathway in Gastrointestinal Stromal Tumors

[0083] Document 4: Severe paraneoplastic hypoglycemia secondary to agastrointestinal stromal tumor masquerading as a stroke

[0084] Document 5: Severe paraneoplastic hypoglycemia in a patient with agastrointestinal stromal tumor with an exon 9mutation a case report.

[0085] Document 6: Hypoglycemia Associated with a Gastrointestinal Stromal TumorProducing High-molecular-weight Insulin Growth Factor II A Case Report and Literature Review;

[0086] Document 7: Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestin.

[0087] (1) Cell experiments

[0088] Using the method of Example 3, the corresponding siRNA was transferred into the gastrointestinal stromal tumor cells GIST-T1 to knock down the expression of growth hormone receptor. It was found that after the expression of growth hormone receptor was reduced, the expression level of insulin-like growth factor 2 (IGF2) was also reduced ( Fig. 9 ).

[0089] (2) Animal experiments

[0090] The KIT gene belongs to the type III tyrosine kinase receptor family and is one of the main oncogenes that cause gastrointestinal stromal tumors (accounting for more than 70%). After the mouse KIT site mutation (V558A) occurs, the mouse can spontaneously develop gastrointestinal stromal tumors. Based on this principle, we commissioned Saiye Biotechnology Co., Ltd. to knock out the growth hormone receptor (GHR gene) in wild C57BL / 6N mice (WT) through CRISPR / Cas-mediated genome engineering, and obtained a GHR gene knockout mouse model (GHR - / - ); The 558th position A of the KIT gene of wild-type C57BL / 6N mice (WT) was mutated to V (V558A) by CRISPR / Cas-mediated genome engineering to obtain a gastrointestinal stromal tumor mouse model (KIT V558A / WT ); The two genotype mice were hybridized and the GHR gene knockout gastrointestinal stromal tumor mouse model (KIT V558A / WT GHR - / - ); observed the blood sugar levels of each mouse, and found that tumor-bearing mice (KIT V558A / WT)The fasting blood glucose level was lower than that of wild-type mice. After the growth hormone receptor expression was knocked out in tumor-bearing mice, the blood glucose level rose again, indicating that the growth hormone receptor can affect the patient's blood glucose level ( Fig.10 ), specifically, growth hormone receptor promotes the expression of insulin-like growth factor 2 (IGF2) affecting the patient's blood sugar level.

[0091] Based on the above content, it can be seen that inhibiting the expression of growth hormone receptor can inhibit the proliferation and / or survival of gastrointestinal stromal tumor cells, promote the apoptosis of gastrointestinal stromal tumor cells, inhibit the activation of AKT, ERK and STAT5 in gastrointestinal stromal tumor cells, increase the sensitivity of gastrointestinal stromal tumors to gastrointestinal stromal tumor targeted drugs, inhibit the expression of insulin-like growth factor 2 in gastrointestinal stromal tumors, improve patients' blood sugar levels, and treat gastrointestinal stromal tumors and / or their complications.

[0092] Although the above embodiment describes the present invention in detail, it is only a part of the embodiments of the present invention, not all of the embodiments. People can also obtain other embodiments based on this embodiment without creativity, and these embodiments all fall within the protection scope of the present invention.

Claims

1. Use of agents or methods for inhibiting growth hormone receptor and / or JAK2 signaling pathway in the preparation of products for treating gastrointestinal stromal tumors and / or their complications.

2. Use of agents or methods that inhibit growth hormone receptor and / or JAK2 signaling pathways in combination with gastrointestinal stromal tumor targeted drugs in the preparation of products for the treatment of gastrointestinal stromal tumors and / or their complications.

3. The use according to claim 2, It is characterized in that The gastrointestinal stromal tumor targeted drug includes imatinib.

4. The use according to any one of claims 1 to 3, It is characterized in that The complications of gastrointestinal stromal tumor include gastrointestinal stromal tumor complicated with hypoglycemia.

5. The use according to any one of claims 1 to 3, It is characterized in that The reagent for inhibiting growth hormone receptor includes siRNA transfection reagent; The agent that inhibits the JAK2 signaling pathway includes Fidatinib.

6. The use according to claim 5, It is characterized in that The siRNA transfection reagent includes siRNA, and the nucleotide sequence of the siRNA is shown as SEQ ID NO.2 or SEQ ID NO.

3.

7. The use according to any one of claims 1 to 3, It is characterized in that The method for inhibiting growth hormone receptor comprises siRNA transfection.

8. The use according to any one of claims 1 to 3, It is characterized in that The products for treating gastrointestinal stromal tumors and / or its complications include one or more of the following: (1) Products that inhibit the proliferation and / or survival of gastrointestinal stromal tumor cells; (2) Products that promote apoptosis of gastrointestinal stromal tumor cells; (3) products that inhibit activation of one or more of AKT, ERK, and STAT5 in gastrointestinal stromal tumor cells; (4) Products that increase the sensitivity of gastrointestinal stromal tumors to gastrointestinal stromal tumor-targeted drugs; (5) Products that inhibit the expression of insulin-like growth factor 2 in gastrointestinal stromal tumors and improve blood sugar levels.

9. A drug for treating gastrointestinal stromal tumors and / or its complications, wherein the active ingredients of the drug include siRNA and / or a JAK2 inhibitor; The nucleotide sequence of the siRNA is shown as SEQ ID NO.2 or SEQ ID NO.

3.

10. The drug according to claim 9, It is characterized in that The active ingredient of the drug also includes a gastrointestinal stromal tumor targeted drug; the gastrointestinal stromal tumor targeted drug includes imatinib.